Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Comprehensive Management of Infantile Hemangiomas Involving the Periorbital Region.

Infantile Hemangioma: Treatment with Surgery or Steroids

Treatment of periorbital infantile haemangiomas: a systematic literature review on propranolol or steroids.

Propranolol Therapy for Infantile Hemangioma: Our Experience

[Oral Propranolol in the Management of Periorbital Proliferating Phase Infantile Hemangioma].

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study

A 7-Year Follow-Up Study on Untreated Deep or Mixed Facial Infantile Hemangioma in East-Asian Patients: when Propranolol Was Not Yet an Option

Timing and Safety of Oral Propranolol for Infantile Hemangioma

Clinical and Radiological Outcomes of Infantile Hemangioma Treated with Oral Propranolol: A Long‐term Follow‐up Study

The Efficacy and Safety of Treatments for Infantile Hemangiomas: a Bayesian Network Meta‐analysis

The efficacy and safety of treatments for infantile hemangiomas: a Bayesian network meta-analysis

Efficacy and Safety of Oral Propranolol or Topical Timolol for the Treatment of Superficial Infantile Hemangiomas

Comparison of Oral Propranolol Alone and Combined with Topical 0.5 ％ Timolol Maleate Cream for the Treatment of Infantile Hemangiomas

Topical Propranolol Hydrochloride Gel for Superficial Infantile Hemangiomas

Effectiveness And Safety Of Oral Propranolol Versus Other Treatments For Infantile Hemangiomas: A Meta-Analysis

Historical and contemporary management of infantile hemangiomas: a single-center experience

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Analysis of Factors Affecting the Therapeutic Effect of Propranolol for Infantile Haemangioma of the Head and Neck

Propranolol for the treatment of infantile hemangiomas: a nine-year monocentric experience from a tertiary hospital

Algorithm-based Management of Infantile Hemangiomas: Reducing Sequelae and Surgical Interventions